JP2019528760A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528760A5
JP2019528760A5 JP2019517047A JP2019517047A JP2019528760A5 JP 2019528760 A5 JP2019528760 A5 JP 2019528760A5 JP 2019517047 A JP2019517047 A JP 2019517047A JP 2019517047 A JP2019517047 A JP 2019517047A JP 2019528760 A5 JP2019528760 A5 JP 2019528760A5
Authority
JP
Japan
Prior art keywords
composition
cells
modified
population
unnatural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528760A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054799 external-priority patent/WO2018064681A1/en
Publication of JP2019528760A publication Critical patent/JP2019528760A/ja
Priority to JP2020168576A priority Critical patent/JP7610948B2/ja
Publication of JP2019528760A5 publication Critical patent/JP2019528760A5/ja
Priority to JP2021156988A priority patent/JP2021191312A/ja
Priority to JP2024076779A priority patent/JP7817312B2/ja
Pending legal-status Critical Current

Links

JP2019517047A 2016-09-30 2017-10-02 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法 Pending JP2019528760A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020168576A JP7610948B2 (ja) 2016-09-30 2020-10-05 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2021156988A JP2021191312A (ja) 2016-09-30 2021-09-27 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2024076779A JP7817312B2 (ja) 2016-09-30 2024-05-09 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662402707P 2016-09-30 2016-09-30
US62/402,707 2016-09-30
US201762502508P 2017-05-05 2017-05-05
US62/502,508 2017-05-05
US201762553058P 2017-08-31 2017-08-31
US62/553,058 2017-08-31
US201762556309P 2017-09-08 2017-09-08
US62/556,309 2017-09-08
PCT/US2017/054799 WO2018064681A1 (en) 2016-09-30 2017-10-02 Modified stem cell memory t cells, methods of making and methods of using same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020168576A Division JP7610948B2 (ja) 2016-09-30 2020-10-05 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2021156988A Division JP2021191312A (ja) 2016-09-30 2021-09-27 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019528760A JP2019528760A (ja) 2019-10-17
JP2019528760A5 true JP2019528760A5 (https=) 2020-11-12

Family

ID=60245180

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019517047A Pending JP2019528760A (ja) 2016-09-30 2017-10-02 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2020168576A Active JP7610948B2 (ja) 2016-09-30 2020-10-05 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2021156988A Pending JP2021191312A (ja) 2016-09-30 2021-09-27 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2024076779A Active JP7817312B2 (ja) 2016-09-30 2024-05-09 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020168576A Active JP7610948B2 (ja) 2016-09-30 2020-10-05 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2021156988A Pending JP2021191312A (ja) 2016-09-30 2021-09-27 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法
JP2024076779A Active JP7817312B2 (ja) 2016-09-30 2024-05-09 改変された幹細胞メモリーt細胞、その作製方法およびその使用方法

Country Status (9)

Country Link
EP (1) EP3519561A1 (https=)
JP (4) JP2019528760A (https=)
KR (4) KR102757155B1 (https=)
CN (1) CN110199015A (https=)
AU (4) AU2017337147A1 (https=)
CA (3) CA3105873A1 (https=)
IL (3) IL287286B (https=)
SG (2) SG11201901959YA (https=)
WO (1) WO2018064681A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901959YA (en) * 2016-09-30 2019-04-29 Poseida Therapeutics Inc Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
AU2017378482B2 (en) 2016-12-16 2024-06-13 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3668972B8 (en) 2017-08-18 2024-11-13 Neutrolis, Inc. Engineered dnase enzymes and use in therapy
US20210015866A1 (en) * 2018-03-23 2021-01-21 La Jolla Institute For Allergy And Immunology Tissue resident memory cell profiles, and uses thereof
AU2019288669B2 (en) 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11058724B2 (en) * 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
AU2019358915B2 (en) 2018-10-08 2025-09-18 Neutrolis, Inc. Engineering of DNASE enzymes for manufacturing and therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
US11529427B2 (en) 2019-02-15 2022-12-20 Crispr Therapeutics Ag Gene editing for hemophilia A with improved factor VIII expression
KR20220004028A (ko) * 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CN110358734B (zh) * 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用
BR112022011339A2 (pt) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc Composições de células terapêuticas e métodos para fabricação e usos das mesmas
WO2021173925A1 (en) * 2020-02-28 2021-09-02 Wisconsin Alumni Research Foundation Nonviral generation of genome edited chimeric antigen receptor t cells
AU2021236391A1 (en) * 2020-03-13 2022-09-29 Capricor, Inc. Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
EP4298205A1 (en) * 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
CN114990061B (zh) * 2022-06-30 2023-08-29 河南省人民医院 一种诱导扩增中央记忆性t细胞的培养方法
CN116444666A (zh) * 2023-05-22 2023-07-18 上海交通大学医学院附属仁济医院 Cdh17特异性诊疗一体化分子影像探针的制备方法及应用
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
CN118272305B (zh) * 2024-04-29 2025-04-08 深圳泽医细胞治疗集团有限公司 一种免疫细胞的培养基及其应用
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU7082694A (en) * 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
US7105343B1 (en) 2000-10-31 2006-09-12 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
MXPA05001992A (es) * 2002-08-19 2005-08-03 Gamida Cell Ltd Expansion ex-vivo de poblaciones de celulas de tallo, hematopoyeticas, en cultivos de celulas mononucleares.
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
JP5456037B2 (ja) * 2009-06-02 2014-03-26 パナソニック株式会社 端末装置及び通信方法、並びに集積回路
US8808748B2 (en) 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
DK2661275T3 (en) 2011-01-07 2019-04-15 Poseida Therapeutics Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING THE HIGH OXYGEN EFFICIENCY TO TUMORS FOR THE ADMINISTRATION
WO2012168304A1 (en) 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protein having nuclease activity, fusion proteins and uses thereof
JP6850528B2 (ja) * 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
JP6346266B2 (ja) * 2013-03-21 2018-06-20 サンガモ セラピューティクス, インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US9534234B2 (en) * 2014-04-09 2017-01-03 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
CA2957552C (en) 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
BR112017004270B1 (pt) * 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
EP3018200A1 (en) * 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
WO2016090111A1 (en) 2014-12-05 2016-06-09 Vindico NanoBio Technology Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3929286A1 (en) * 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
SG11201901959YA (en) 2016-09-30 2019-04-29 Poseida Therapeutics Inc Modified stem cell memory t cells, methods of making and methods of using same

Similar Documents

Publication Publication Date Title
JP2019528760A5 (https=)
Tsvetkov Worldview model as the result of education
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
EP4427809A3 (en) Altering gene expression in car-t cells and uses thereof
JP2013176400A5 (https=)
IL287286B (en) Differentiated stem cell memory t cells, methods for their preparation and methods for using them
JP2013501505A5 (https=)
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
EA201890772A1 (ru) Способ высокоуровневого и стабильного переноса генов в лимфоцитах
HK1216894A1 (zh) 多價結合蛋白組合物
NZ705675A (en) Engineered transgene integration platform (etip) for gene targeting and trait stacking
JP2014520551A5 (https=)
MX367170B (es) Enriquecimiento de la clasificacion de las celulas activadas por fluorescencia (facs) para generar plantas.
MX369077B (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
JP2016500260A5 (https=)
EP4218409A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
CY1123348T1 (el) Μεθοδος για την παρασκευη ενισχυμενων πολυδυναμων βλαστοκυτταρων απο μεσεγχυματικα βλαστοκυτταρα με τη χρηση κλασματος φλοροταννινης
Plekhanova et al. The development of mass media in the modern information society
JP2019534684A5 (https=)
PL415351A1 (pl) Sposób namnażania in vitro komórek T regulatorowych (Treg)
JP2013503602A5 (https=)
JP2014533495A5 (https=)
Belov et al. IMPLEMENTATION OF KNOWLEDGE CONTROL ELEMENTS INTO EDUCATIONAL ENVIRONMENT OF" DUBNA" UNIVERSITY. EXPERIENCES AND PERSPECTIVES